Novabay Pharmaceuticals Inc Коэффициент "короткого" интереса
Что обозначает Коэффициент "короткого" интереса в Novabay Pharmaceuticals Inc?
Коэффициент "короткого" интереса Novabay Pharmaceuticals Inc является 0.58
Какое определение для Коэффициент "короткого" интереса?
Краткосрочный коэффициент - это количество проданных акций, которых нет в наличии, деленное на среднесуточный объем.
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
Коэффициент "короткого" интереса компаний в Health Care сектор на NYSEMKT по сравнению с Novabay Pharmaceuticals Inc
Что делает Novabay Pharmaceuticals Inc?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Компании с коэффициент "короткого" интереса похож на Novabay Pharmaceuticals Inc
- L.S. Starrett Co имеет Коэффициент "короткого" интереса из 0.57
- J. Alexanders Inc имеет Коэффициент "короткого" интереса из 0.57
- Commerce Bancshares, (Missouri) имеет Коэффициент "короткого" интереса из 0.57
- Revelo Resources имеет Коэффициент "короткого" интереса из 0.57
- Cemtrex имеет Коэффициент "короткого" интереса из 0.57
- Tenaz Corp имеет Коэффициент "короткого" интереса из 0.57
- Novabay Pharmaceuticals Inc имеет Коэффициент "короткого" интереса из 0.58
- LSI Industries имеет Коэффициент "короткого" интереса из 0.59
- Alio Gold имеет Коэффициент "короткого" интереса из 0.59
- Gensource Potash имеет Коэффициент "короткого" интереса из 0.59
- Quintana Services имеет Коэффициент "короткого" интереса из 0.59
- Sylla Gold Corp имеет Коэффициент "короткого" интереса из 0.59
- Marvel Discovery имеет Коэффициент "короткого" интереса из 0.59